Indinavir: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
! colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref><ref>L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.</ref><ref>J. Ford, et al. Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother. 2004 July; 48(7): 2388–2393.</ref><ref>PMID:10620574</ref><ref>PMID:16086644</ref> | ! colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref><ref>L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.</ref><ref>J. Ford, et al. Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother. 2004 July; 48(7): 2388–2393.</ref><ref>PMID:10620574</ref><ref>PMID:16086644</ref><ref>PMID:19131522</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 35: | Line 35: | ||
! Fosamprenavir | ! Fosamprenavir | ||
! Lopinavir | ! Lopinavir | ||
! | ! .5 | ||
! 2-4 | ! 2-4 | ||
! Nelfinavir | ! Nelfinavir | ||
| Line 47: | Line 47: | ||
! Fosamprenavir | ! Fosamprenavir | ||
! Lopinavir | ! Lopinavir | ||
! | ! 2730 | ||
! ~4393 | ! ~4393 | ||
! 4381 | ! 4381 | ||
| Line 76: | Line 76: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! 4. | ! 4.8 | ||
! 4.2 | ! 4.2 | ||
! 1.8 | ! 1.8 | ||
! 4.5 | ! 4.5 | ||
! 5. | ! 5.5 | ||
! Fosamprenavir | ! Fosamprenavir | ||
! Lopinavir | ! Lopinavir | ||
! | ! 29.4 | ||
! 5. | ! 5.3 | ||
! 3.3 | ! 3.3 | ||
|- | |- | ||
| Line 95: | Line 95: | ||
! Fosamprenavir | ! Fosamprenavir | ||
! Lopinavir | ! Lopinavir | ||
! | ! 4746 | ||
! ~26045 | ! ~26045 | ||
! 27000 | ! 27000 | ||
| Line 131: | Line 131: | ||
! Fosamprenavir | ! Fosamprenavir | ||
! Lopinavir | ! Lopinavir | ||
! | ! 400 | ||
! 400 | ! 400 | ||
! 750 | ! 750 | ||
| Line 143: | Line 143: | ||
! Hepatic (CYP3A4) | ! Hepatic (CYP3A4) | ||
! Hepatic (CYP3A4) | ! Hepatic (CYP3A4) | ||
! | ! Hepatic (CYP3A4) | ||
! Atazanavir | ! Atazanavir | ||
! Nelfinavir | ! Nelfinavir | ||
